Pfizer Inc (PFE)

Gross profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Gross profit (ttm)	US$ in thousands	14,853,000	24,781,000	37,247,000	46,963,000	47,910,000	48,602,000	46,954,000	40,234,000	34,570,000	28,517,000	22,285,000	19,281,000	18,170,000	19,660,000	20,562,000	21,649,000	21,938,000	22,532,000	23,140,000	22,880,000
Revenue (ttm)	US$ in thousands	58,497,000	68,538,000	77,944,000	92,952,000	100,331,000	100,771,000	101,921,000	92,738,000	81,285,000	63,407,000	51,332,000	44,201,000	41,650,000	47,096,000	47,667,000	49,131,000	50,098,000	51,534,000	52,176,000	52,443,000
Gross profit margin		25.39%	36.16%	47.79%	50.52%	47.75%	48.23%	46.07%	43.38%	42.53%	44.97%	43.41%	43.62%	43.63%	41.74%	43.14%	44.06%	43.79%	43.72%	44.35%	43.63%

December 31, 2023 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $14,853,000K ÷ $58,497,000K
= 25.39%

The gross profit margin of Pfizer Inc. has shown fluctuations over the past eight quarters. In Q2 and Q3 2023, the gross profit margin reached relatively high levels of 69.42% and 60.55%, respectively. However, in Q4 2023, the margin decreased to 57.34%. Comparing these figures to the previous year, there has been an overall improvement in the company's performance, as the margins in 2023 generally exceeded those in 2022. This indicates that Pfizer has been effectively managing its cost of goods sold relative to its revenue in recent quarters. Further analysis on the drivers behind these fluctuations, such as changes in product mix, pricing strategies, or production efficiencies, would provide additional insights into the company's financial performance.